131 related articles for article (PubMed ID: 26283007)
1. Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma.
Su L; Wang H; Miao J; Liang Y
Sci Rep; 2015 Aug; 5():13238. PubMed ID: 26283007
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter hypermethylation of p16 gene in endometrial carcinoma.
Hu ZY; Tang LD; Zhou Q; Xiao L; Cao Y
Tumour Biol; 2015 Mar; 36(3):1487-91. PubMed ID: 25596080
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.
Tang B; Li Y; Qi G; Yuan S; Wang Z; Yu S; Li B; He S
Sci Rep; 2015 Sep; 5():13563. PubMed ID: 26338139
[TBL] [Abstract][Full Text] [Related]
4. [Methylation and expression of the p16 gene in endometrial carcinoma].
Chao H; Sun J; Lu S
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):228-31. PubMed ID: 11778238
[TBL] [Abstract][Full Text] [Related]
5. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.
Liau JY; Liao SL; Hsiao CH; Lin MC; Chang HC; Kuo KT
Hum Pathol; 2014 Mar; 45(3):533-9. PubMed ID: 24440092
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A methylation in esophageal cancer: a meta-analysis.
Zhou C; Li J; Li Q
Oncotarget; 2017 Jul; 8(30):50071-50083. PubMed ID: 28637022
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
9. Common genetic variants in the 9p21 region and their associations with multiple tumours.
Gu F; Pfeiffer RM; Bhattacharjee S; Han SS; Taylor PR; Berndt S; Yang H; Sigurdson AJ; Toro J; Mirabello L; Greene MH; Freedman ND; Abnet CC; Dawsey SM; Hu N; Qiao YL; Ding T; Brenner AV; Garcia-Closas M; Hayes R; Brinton LA; Lissowska J; Wentzensen N; Kratz C; Moore LE; Ziegler RG; Chow WH; Savage SA; Burdette L; Yeager M; Chanock SJ; Chatterjee N; Tucker MA; Goldstein AM; Yang XR
Br J Cancer; 2013 Apr; 108(6):1378-86. PubMed ID: 23361049
[TBL] [Abstract][Full Text] [Related]
10. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
Wang Z; Wang B; Guo H; Shi G; Hong X
Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
[TBL] [Abstract][Full Text] [Related]
12. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.
Andujar P; Wang J; Descatha A; Galateau-Sallé F; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Renier A; Zucman-Rossi J; Pairon JC; Jaurand MC
Lung Cancer; 2010 Jan; 67(1):23-30. PubMed ID: 19375815
[TBL] [Abstract][Full Text] [Related]
13. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
[TBL] [Abstract][Full Text] [Related]
14. The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.
Tsuda H; Yamamoto K; Inoue T; Uchiyama I; Umesaki N
Br J Cancer; 2000 Feb; 82(3):675-82. PubMed ID: 10682682
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex.
Alves MK; Faria MH; Neves Filho EH; Ferrasi AC; Pardini MI; de Moraes Filho MO; Rabenhorst SH
Int J Surg; 2013; 11(7):549-53. PubMed ID: 23721661
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas.
Simpson DJ; Bicknell JE; McNicol AM; Clayton RN; Farrell WE
Genes Chromosomes Cancer; 1999 Apr; 24(4):328-36. PubMed ID: 10092131
[TBL] [Abstract][Full Text] [Related]
17. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.
Huang T; Chen X; Hong Q; Deng Z; Ma H; Xin Y; Fang Y; Ye H; Wang R; Zhang C; Ye M; Duan S
Sci Rep; 2015 Mar; 5():8897. PubMed ID: 25754026
[TBL] [Abstract][Full Text] [Related]
18. The relationship between five widely-evaluated variants in CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis.
Peng F; Hu D; Gu C; Li X; Li Y; Jia N; Chu S; Lin J; Niu W
Gene; 2013 Dec; 531(2):435-43. PubMed ID: 24012816
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
20. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
